Amisulpride
- Generic Name
- Amisulpride
- Brand Names
- Barhemsys
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27N3O4S
- CAS Number
- 71675-85-9
- Unique Ingredient Identifier
- 8110R61I4U
- Background
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride ...
- Indication
Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not receive...
- Associated Conditions
- Acute Schizophrenia, Chronic Schizophrenia, Negative Symptoms, Post Operative Nausea and Vomiting (PONV)
- Associated Therapies
- -
Amisulpride in Schizophrenic Acute Phase Patients
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00436371
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- University of Jena
- Target Recruit Count
- 19
- Registration Number
- NCT00419653
Amisulpride in Schizophrenic Patients
- Conditions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 138
- Registration Number
- NCT00331981
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
SOLIACS: Solian Solution in the Acute Setting
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT00245674
- Locations
- 🇧🇪
Sanofi-aventis, Diegem, Belgium
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 124
- Registration Number
- NCT00204061
- Locations
- 🇩🇪
Department of Psychiatry and Psycotherapy University of Cologne, Cologne, North Rhine-Westphalia, Germany
SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients
- Conditions
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT00126009
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.